Semaglutide for kidney disease linked to fatty liver and diabetes
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether the oral medication semaglutide can help treat chronic kidney disease in people who have both type 2 diabetes and a fatty liver related to metabolism. It aims to see if the drug can improve kidney function and liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have type 2 diabetes
- Your A1C (a measure of blood sugar) is 10% or less
- Your kidney function is moderately reduced (eGFR between 25 and 75) and you have protein in your urine (UACR greater than 100)
- You are already taking a stable dose of blood pressure medication (ACE inhibitor or ARB) for at least 4 weeks
- You do not have other causes of liver disease like hepatitis or heavy alcohol use, and you have not been on GLP-1 medications like semaglutide in the last 90 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
This study tests if semaglutide (a GLP-1 RA medicine) can reduce alcohol consumption and improve liver fat and metabolism in people with obesity and fatty liver disease who drink above certain levels.
Hear when a new MAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.